Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET

Annals of Nuclear Medicine

Volumn 22, Issue 5, 2008, Pages 429-432

  Fanti, Stefano ^a   Castellucci, Paolo ^a   Stefoni, Vittorio ^a   Nanni, Cristina ^a   Tani, Monica ^a   Rubello, Domenico ^b   Ambrosini, Valentina ^a   Zinzani, Pier Luigi ^a   Franchi, Roberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Ospedale S Maria della Misericordia   (Italy)

Author keywords

FDG diagnostic use; Hodgkin's lymphoma; Positron emission tomography

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ANAMNESIS; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; FALSE NEGATIVE REACTIONS; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECURRENCE;

EID: 46649101842     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-008-0105-8     Document Type: Article

References (8)

1. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006;47:1326-1334.
2. Spaepen K, Stroobants S, Verhoef G, Mortelmans L. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S97-105.
3. Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, et al. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging 2005;32:749-756.
4. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514-1523.
5. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin's lymphoma. Ann Oncol 2005;16:1160-1168.
6. Kostakoglu L, Coleman M, Leonard JP, Zoe H, Goldsmith SJ. PET predict prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43:1018-1027.
7. Strobel K, Schaefer NG, Renner C, Veilt-Haibach P, Husarik D, Koma AY, et al. Cost-effectiveness therapy remission assessment in lymphoma patients using FDG-PET/CT: is an end of treatment exam necessary in all patients? Ann Oncol 2007;18:658-664.
8. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scannino performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91:475-481.